{"nctId":"NCT00482677","briefTitle":"Radiation Therapy With or Without Temozolomide in Treating Older Patients With Newly Diagnosed Glioblastoma Multiforme","startDateStruct":{"date":"2007-11-14","type":"ACTUAL"},"conditions":["Brain and Central Nervous System Tumors"],"count":562,"armGroups":[{"label":"Temozolomide","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: temozolomide","Genetic: DNA methylation analysis","Procedure: quality-of-life assessment"]},{"label":"Radiation","type":"ACTIVE_COMPARATOR","interventionNames":["Genetic: DNA methylation analysis","Procedure: quality-of-life assessment","Radiation: Radiation"]}],"interventions":[{"name":"temozolomide","otherNames":[]},{"name":"DNA methylation analysis","otherNames":[]},{"name":"quality-of-life assessment","otherNames":[]},{"name":"Radiation","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"DISEASE CHARACTERISTICS:\n\n* Histopathologically confirmed glioblastoma multiforme\n\n  * Grade IV disease by WHO classification\n  * Newly diagnosed disease\n* Initial diagnostic surgery or biopsy performed within the past 4 weeks\n* Not a candidate for standard radiotherapy (60Gy/30 fractions over 6 weeks) in combination with temozolomide\n\nPATIENT CHARACTERISTICS:\n\n* ECOG performance status 0-2\n* Absolute granulocyte count ≥ 1,500/mm³\n* Platelet count ≥ 100,000/mm³\n* Creatinine ≤ 1.5 times upper limit of normal (ULN)\n* Bilirubin ≤ 1.5 times ULN\n* ALT and AST \\< 2.5 times ULN\n* No known hypersensitivity to temozolomide or compounds with similar chemical composition to temozolomide\n* No history of other malignancies except adequately treated nonmelanoma skin cancer, curatively treated in situ cancer of the cervix, or other curatively treated solid tumors with no evidence of disease for at least 5 years\n* No serious active infection (e.g., wound infection requiring parenteral antibiotics) or other serious underlying medical conditions that would preclude study treatment\n* No other condition (e.g., psychological or geographical) that would preclude study compliance\n\nPRIOR CONCURRENT THERAPY:\n\n* No prior chemotherapy\n* No prior radiotherapy\n* No prior or concurrent investigational therapy\n* No concurrent surgical procedures for tumor debulking\n* No concurrent stereotactic boost radiotherapy\n* No other concurrent chemotherapy, immunotherapy, or biological therapy\n* No concurrent epoetin alfa\n* Concurrent corticosteroids allowed provided the patient has been on a stable or decreasing dose for at least 14 days","healthyVolunteers":false,"sex":"ALL","minimumAge":"65 Years","maximumAge":"120 Years","stdAges":["OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Overall Survival","description":"Time from date of randomization to the date of death of any causes, or censored at last known alive date.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.33","spread":null},{"groupId":"OG001","value":"7.62","spread":null}]}]}]},{"type":"SECONDARY","title":"Progression-free Survival","description":"Time from date of randomization to the date of disease progression or death whichever came first, or censored at last disease assessment date.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.29","spread":null},{"groupId":"OG001","value":"3.94","spread":null}]}]}]},{"type":"SECONDARY","title":"Adverse Events","description":"Evaluated according to CTCAE V3.0","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Methylation Status of the O6-methylguanine-DNA Methyltransferase Promoter","description":"Overall survival for patients by Methylation status of the O6-methylguanine-DNA methyltransferase promoter","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.47","spread":null},{"groupId":"OG001","value":"7.69","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":158,"n":271},"commonTop":["Fatigue","Alopecia","Speech impairment","Neuropathy-motor","Pain Head/headache"]}}}